Bexion Pharmaceuticals
October 18, 2023
Franciscan C
Oncology
Bexion is a clinical stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy. The Company’s lead asset BXQ-350 activates Sphingolipid Metabolism and is entering into a Phase 2 trial of combination therapy in newly diagnosed metastatic colorectal cancer (mCRC) and a Phase 1 PK/PD proof of concept trial on prevention/reversal of CIPN.
Company Type
Privately Funded
Website
https://www.bexionpharma.com/
CEO/Top Company Official
Scott Shively
Lead Product in Development
BXQ-350
Number Of Unlicensed Products
1
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)